Published in Br J Cancer on January 01, 1997
Sun exposure and risk of melanoma. Arch Dis Child (2005) 1.40
Teen smoking, field cancerization, and a "critical period" hypothesis for lung cancer susceptibility. Environ Health Perspect (2002) 1.14
Selection of controls in case-control studies. II. Types of controls. Am J Epidemiol (1992) 3.80
Personal risk-factor chart for cutaneous melanoma. Lancet (1989) 2.65
Nonfamilial cutaneous melanoma incidence in women associated with sun exposure before 20 years of age. Pediatrics (1989) 2.61
Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. J Invest Dermatol (1977) 2.53
Cutaneous malignant melanoma and indicators of total accumulated exposure to the sun: an analysis separating histogenetic types. J Natl Cancer Inst (1984) 2.39
Suntan, sunburn, and pigmentation factors and the frequency of acquired melanocytic nevi in children. Similarities to melanoma: the Vancouver Mole Study. Arch Dermatol (1990) 1.46
Malignant melanoma in relation to moles, pigmentation, and exposure to fluorescent and other lighting sources. Br J Cancer (1986) 1.32
Mortality from melanoma in migrants to Australia: variation by age at arrival and duration of stay. Am J Epidemiol (1992) 1.20
Seasonality of presentation of cutaneous melanoma, squamous cell cancer and basal cell cancer in the Oxford Region. Br J Cancer (1985) 1.16
Sun exposure and melanocytic naevi in young Australian children. Lancet (1994) 1.15
Malignant melanoma: aetiological importance of individual pigmentation and sun exposure. Br J Dermatol (1990) 1.13
Malignant melanoma risk by nativity, place of residence at diagnosis, and age at migration. Cancer Causes Control (1991) 0.98
Variation and covariates of the number of benign nevi in adolescents. Am J Epidemiol (1992) 0.89
Seasonal variation in frequency of diagnosis of cutaneous malignant melanoma. Melanoma Res (1994) 0.88
Malignant melanoma in World War II veterans. Int J Dermatol (1984) 0.84
Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science (1996) 6.02
Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke (2001) 4.87
Variation of sensitivity, specificity, likelihood ratios and predictive values with disease prevalence. Stat Med (1997) 3.79
Sunscreen use and duration of sun exposure: a double-blind, randomized trial. J Natl Cancer Inst (1999) 3.75
An alternative approach to monitoring cancer patient survival. Cancer (1996) 3.59
Sunscreen use, wearing clothes, and number of nevi in 6- to 7-year-old European children. European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Natl Cancer Inst (1998) 3.49
Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med (1977) 3.45
High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med (1999) 2.98
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol (2002) 2.86
Immunization with irradiated tumour cells and specific lymphocyte cytotoxicity in malignant melanoma. Br Med J (1971) 2.82
Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer (1982) 2.71
Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol (1998) 2.35
Diagnosis of Creutzfeldt-Jakob disease by measurement of S100 protein in serum: prospective case-control study. BMJ (1998) 2.15
TIA-1 and TIAR activate splicing of alternative exons with weak 5' splice sites followed by a U-rich stretch on their own pre-mRNAs. J Biol Chem (2001) 1.96
Sequential and average attributable fractions as aids in the selection of preventive strategies. J Clin Epidemiol (1995) 1.94
Diagnosis of Creutzfeldt-Jakob disease by two-dimensional gel electrophoresis of cerebrospinal fluid. Lancet (1996) 1.91
Cell-mediate cytotoxicity in vitro of human lymphocytes against a tissue culture melanoma cell line (igr3). J Immunol (1975) 1.82
UV-damaged DNA-binding protein in the TFTC complex links DNA damage recognition to nucleosome acetylation. EMBO J (2001) 1.81
Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single versus multiple doses of Curosurf. Pediatrics (1992) 1.71
Period analysis for 'up-to-date' cancer survival data: theory, empirical evaluation, computational realisation and applications. Eur J Cancer (2004) 1.68
Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed (1995) 1.60
Risk and rate advancement periods as measures of exposure impact on the occurrence of chronic diseases. Epidemiology (1993) 1.57
Advanced breast cancer incidence following population-based mammographic screening. Ann Oncol (2011) 1.53
Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J Immunol (1997) 1.52
Hypercalcaemia in B cell chronic lymphocytic leukaemia. Br J Haematol (1994) 1.50
Current clinical diagnosis in Creutzfeldt-Jakob disease: identification of uncommon variants. Ann Neurol (2000) 1.49
Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res (2000) 1.47
A comparison of patterns of sun protection during beach holidays and everyday outdoor activities in a population sample of young German children. Br J Dermatol (2012) 1.43
Erythroblastic and/or megakaryoblastic leukemia in Down syndrome: treatment with low-dose arabinosyl cytosine. J Pediatr Hematol Oncol (1996) 1.42
The importance of context information in the diagnostic rating of digital images of patch test reactions. Br J Dermatol (2009) 1.40
The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther (2003) 1.40
Cytology alone versus cytology and cervicography for cervical and cervicography for cervical cancer screening: a randomized study. European Society for Oncological Research. Obstet Gynecol (1999) 1.39
Patch testing with methyldibromoglutaronitrile. Am J Contact Dermat (2000) 1.39
[Boundaries between ambulatory and inpatient medicine from the viewpoint of an established oncologist in internal medicine]. Med Klin (Munich) (1994) 1.38
A computer program for period analysis of cancer patient survival. Eur J Cancer (2002) 1.32
Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients. J Immunol (2000) 1.31
Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life. Proc Natl Acad Sci U S A (2001) 1.31
Melanoma and use of sunscreens: an Eortc case-control study in Germany, Belgium and France. The EORTC Melanoma Cooperative Group. Int J Cancer (1995) 1.30
Deriving more up-to-date estimates of long-term patient survival. J Clin Epidemiol (1997) 1.28
Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization. J Pharmacol Exp Ther (2001) 1.28
Cutaneous malignant melanoma and exposure to sunlamps or sunbeds: an EORTC multicenter case-control study in Belgium, France and Germany. EORTC Melanoma Cooperative Group. Int J Cancer (1994) 1.27
Endocrine and hemodynamic effects of stress versus systemic CRF in alcoholics during early and medium term abstinence. Alcohol Clin Exp Res (1997) 1.27
Influence of sun exposures during childhood and during adulthood on melanoma risk. EPIMEL and EORTC Melanoma Cooperative Group. European Organisation for Research and Treatment of Cancer. Int J Cancer (1998) 1.26
Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. J Immunol (2001) 1.24
S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurol (1997) 1.24
Use of the positive predictive value to correct for disease misclassification in epidemiologic studies. Am J Epidemiol (1993) 1.23
The evolution of boosting algorithms. From machine learning to statistical modelling. Methods Inf Med (2014) 1.22
Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha). Int J Cancer (1994) 1.22
Lipid composition of human malignant melanoma tumors at various levels of malignant growth. Eur J Biochem (1979) 1.21
On the release and half-life of S100B protein in the peripheral blood of melanoma patients. Int J Cancer (2001) 1.20
[Ultrastructure of the wall of Neisseria meningitidis]. Ann Inst Pasteur (Paris) (1967) 1.15
Extending statistical boosting. An overview of recent methodological developments. Methods Inf Med (2014) 1.15
A monoclonal antibody (LYP18) directed against the blood platelet glycoprotein IIb/IIIa complex inhibits human melanoma growth in vivo. Blood (1989) 1.14
IL-6 gene amplification and expression in human glioblastomas. Br J Cancer (2001) 1.14
Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma. J Immunol (2000) 1.13
Partitioning methods for multifactorial risk attribution. Stat Methods Med Res (2001) 1.12
Simultaneous determination of deoxyribonucleoside in the presence of ribonucleoside triphosphates in human carcinoma cells by high-performance liquid chromatography. Anal Biochem (1999) 1.12
Difficulties encountered in the application of Clark classification and the Breslow thickness measurement in cutaneous malignant melanoma. Int J Cancer (1980) 1.12
Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer (1993) 1.10
Distinct reactivity of Burkitt's lymphoma cell lines with eight monoclonal antibodies correlated with the ethnic origin. J Natl Cancer Inst (1984) 1.10
Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Clin Cancer Res (2001) 1.08
Chemotactic factor and P15E-related chemotaxis inhibitor in human melanoma cell lines with different macrophage content and tumorigenicity in nude mice. J Immunol (1987) 1.08
Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Members of the Collaborative European Multicenter Study Group. Pediatrics (2000) 1.07
The case for sunscreens revisited. Arch Dermatol (1998) 1.07
A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med (1982) 1.06
S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther (2001) 1.05
Neutrophil elastase and acute pulmonary damage in neonates with severe respiratory distress syndrome. Pediatrics (1993) 1.05
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Ann Oncol (1999) 1.04
The body site distribution of melanocytic naevi in 6-7 year old European children. Melanoma Res (2001) 1.04
Memorandum "Open Metadata". Open Access to Documentation Forms and Item Catalogs in Healthcare. Methods Inf Med (2015) 1.04
Recent advances in the ultrastructure of malignant melanoma. Rev Eur Etud Clin Biol (1971) 1.02
Validity of the histopathological criteria used for diagnosing dysplastic naevi. An interobserver study by the pathology subgroup of the EORTC Malignant Melanoma Cooperative Group. Eur J Cancer (1993) 1.01
Stage I melanoma of the limbs. Immediate versus delayed node dissection. Tumori (1980) 1.01
Human CD8(+) T cells expressing HLA-DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells. Eur J Immunol (2001) 1.00
Light-emitting diodes (LED) for domestic lighting: any risks for the eye? Prog Retin Eye Res (2011) 1.00
Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci (2000) 1.00
Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? Ann Oncol (2005) 0.99
The effects of joint misclassification of exposure and disease on epidemiologic measures of association. J Clin Epidemiol (1993) 0.99
Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol (1997) 0.99
Variant translocation in a non endemic case of Burkitt's lymphoma: t (8;22) in an Epstein--Barr virus negative tumour and in a derived cell line. Eur J Cancer (1981) 0.98
A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. J Pharmacol Exp Ther (1998) 0.97
Impact of vaccinations and infectious diseases on the risk of melanoma--evaluation of an EORTC case-control study. Eur J Cancer (2003) 0.97